EXAD Archives - Blue Horseshoe Stocks

Blue Horseshoe Stocks: Options Recap & More

Seagate Technologies plc. STX – Options Recap

Although it would end up reversing and heading lower as the day progressed, STX did ride the bullish wave off of its healthy earnings beat for a solid upswing inside the first hour of trading yesterday.

That did facilitate a window of opportunity on the options contracts we were tracking, the STX Weekly $41-43.50 Calls. Traders who were quick on the draw yesterday morning could have taken away a piece of the following moves:

$41 Calls – Range: 1.78-5.28 – Max Gain: 196%
$41.50 Calls – Range: 2.00-4.48 – Max Gain: 124%
$42 Calls – Range: 1.99-4.50 – Max Gain: 126%
$42.50 Calls – Range: 2.11-3.45 – Max Gain: 63%
$43 Calls – Range: .86-3.00 – Max Gain: 249%
$43.50 Calls – Range: .78-2.77 – Max Gain: 255%

We did signal our hunch that there would be a reversal in-session and a corresponding idea for the Weekly $46 Puts in our live traders chat, and those ended up doing quite well also, subsequently running from .60-3.29 (+448%) as STX continued to consolidate into the close.

It’s another example of why we urge any of our readers that want to get in on our daily traders chats to get a Skype contact request over to username ‘stocksumo’. That’s all it takes, and you can stay up to the minute on changing ideas throughout the day, and submit some of your own!

Avinger, Inc. AVGR

The current situation with the AVGR chart has caught our eye this midweek as the stock reversed course this week after a steep and rapid decline. We’re seeing increased activity in the premarket and AVGR has pushed its way up regaining much of the ground it has recently lost.

Currently trading around the 3.00 mark, a return to its recent swing high from roughly a month ago would mean gains of up to 50% so we’ll be monitoring AVGR over coming sessions for a possible continuation of the recovery that is presently in effect.

Extended Watchlist:
ALKM, PNTV, RJDG, LEXG, EXAD, EEGI, GNBT,

Blue Horseshoe Stocks: MYHI Run Continues, Options & More

Mountain High Acquisitions Corp. MYHI

Yesterday morning’s first mention was MYHI, which we had tracked the day prior over an impressive 94% span ranging from a low of .09 to .1745 on the first trading day of the new year.

We said we’d stay on MYHI’s trail after that momentous push, and the stock responded well with another bullish session yesterday wherein it achieved a new high of .239, and closed with strength yet again. From Tuesday;’s low of .09, yesterday’s high represents a two-session upswing of 166%

We’ll reiterate yesterday morning’s sentiment in saying that we’ll continue to monitor MYHI for further recording of higher highs and higher lows, and at some point, we expect a consolidation that should lead to a dip-and-rip pattern on the chart.

Connexus Corp. CNXS

Also appearing in yesterday’s premarket report was CNXS, which went on to have quite a solid session itself, particularly in the early goings.

The stock traded in a range from .001 to .0028 inside of the first 90 minutes of trading, which comes out to an intraday rip of 180% It managed to close just above both its current 50 and 200DMA’s so we’ll definitely want to keep a space on our watch screens reserved for CNXS in sessions ahead.

Abercrombie & Fitch Co. ANF – Options Update

ANF did our bidding to a tee yesterday. While we did signal a range of extended-term options contracts, we made it a point to mention that the gain opportunities could be there right from the start. We turned out to be spot-on in that regard.

We highlighted the ANF 02/17 $12-15 Calls, which all provided chances to profit right from the word go. That being said, with loads of time before expiration, we’ll be very interested to see how a continued uptrend for ANF and the magnitude of the added gains that would facilitate.

$12 Calls – Range: 1.10-1.40 – Max Gain: 27%
$13 Calls – Range: .60-.79 – Max Gain: 32%
$14 Calls – Range: .32-.44 – Max Gain: 38%
$15 Calls – Range: .12-.20 – Max Gain: 67%

StoneMor Partners L.P. STON

We’ve spotted a bottom-bouncer in STON this morning that appears to have loads of upside potential. We’ve included a chart below, and pointed out the various aspects that have us interested in tracking the stock’s activity in sessions ahead. On top of that, we’re also taking into consideration the Form-4’s for a string of big insider buys that were made in the past week.

Should it prove able to break through resistance around the present 50DMA in the low 10.50’s, things could get more than a little interesting.

Extended Watchlist:
SFOR, EXAD, GYOG, LEXG,
NUGT($9-9.50 Calls, if it can break 50DMA)

Blue Horseshoe Stocks: Pharma News Watchlist & More

Pharma News Watchlist:

We’ve got a trio of pharma plays to add to our watchlist on the heels of fresh news releases for each of them this morning. Each stock is gapping up significantly in the premarket, and we’ll be waiting in the wings once the session commences to see if we can use the resulting activity to our advantage.

Akebia Therapeutics, Inc. AKBA – Per the newly announced agreement out today, AKBA has entered into a Collaboration and License Agreement to carry forward with the development of one of its treatments. The deal comes with an immediate payment of $125M, a cash infusion that represents roughly 40% of the company’s total market cap as of yesterday.

______

ACADIA Pharmaceuticals, Inc. ACAD – In the case of ACAD, we’ve gotten word of positive top-line results in a Phase II study it was conducting on the company’s Alzheimer’s drug. To leverage the present activity to our advantage here, we’re going to track the ACAD Weekly $28-31 Calls. (>>View PR)

_______

Conatus Pharmaceuticals, Inc. CNAT

Here we have another collaboration and licensing deal, for CNAT’s liver drug, which is going to be bringing a $50M cash infusion Conatus’ way. That’s just the initial tranche, with more payments to follow as outlined in the relevant filing (>>View 8-K)

Globalstar, Inc. GSAT

We put GSAT on watch as a possible momentum play in yesterday morning’s premarket report, and while it didn’t break out in a major way, it did continue the trend of solid upward momentum that has been observed in recent sessions. From an early low of 1.25, the stock ran as high as 1.60; a 28% pop.

The performance, while not astronomical, was certainly enough to hold our interest in continuing to monitor GSAT’s activity moving forward.

Cellectar Biosciences, Inc. CLRB – Reminder

We just wanted to take a quick moment to reiterate a possible bottom-play selection we made last week in the form of CLRB. We’re still tracking this one, and think it has a good chance to produce a recovery, possibly following the holiday break. So we’re going to want to leave a space on our watch screens reserved for CLRB in the days and weeks ahead.

Extended Watchlist:
AXPW, CAPS, MFST, ENDV, ETRM, EXAD

Blue Horseshoe Stocks: IDXG Update & More

Interpace Diagnostics Group, Inc. IDXG

We tracked IDXG last week over a couple of stellar sessions that led to a swing of more than 400%, cautioning that a dip-and-rip could be in the cards after seeing such a volatile move to the upside.

That’s exactly what we’ve seen in the past couple of days, as IDXG came down to find support at the .865 level, and in the ensuing three sessions it’s been steadily registering higher highs and higher lows, getting back to 1.25 yesterday (+45%).

We’ll continue to follow this story, which kicked off with the revelation that Aetna would cover Interpace’s ThyraMir™ test for its 46 million insured members. (>>View PR)

Experience Art & Design, Inc. EXAD

We had EXAD tagged in yesterday’s premarket report and this subpenny play produced a moderate run to kick off the session, even as the larger markets were struggling with the Fed rate hike announcement.

From an early low of .0023, the stock took just the first hour of trading to find its way up to a high of .0038, for a 65% pop. IDXG hung around that level until around lunchtime, and it did come back down to its daily low toward the close, so we’ll be looking for the possibility of a rebound.

Catalyst Biosciences, Inc. CBIO

We’re also interested in following the activity of CBIO today, which is gapping up in the premarket to the tune of more than 100% and looks like it could be lining up to have a big day. We’ll want to make sure it holds above its 50DMA (.80) on any pullbacks, but if it can breach past its 200DMA of 1.31, things could get very interesting.

News broke yesterday via an 8-K filing that CBIO had entered into a definitive agreement with Wyeth LLC, (wholly-owned subsidiary of Pfizer Inc.) to transfer exclusive rights to research, develop, manufacture and commercialize Factor VIIa variants, CB 813a and CB 813d, as well as transferring the investigational NDA to CBIO as well. (>>View Filing)

Fresh Options Idea: Transocean, Inc. RIG $15 and $14.50 Puts

Extended Watchlist:
VCEL, NWBO, BCLI, BPMX, DLOV, PPMT

Blue Horseshoe Stocks: QFOR, NDEV Updates & More

Quadrant 4 Systems Corp. QFOR

Yesterday marked the first time we ever mentioned QFOR in any of our premarket reports, and in a stroke of fantastic timing, the stock made one heck of a debut for us.

We were interested because we noticed that after taking a huge beating from nearly .20 at the beginning of the month, the stock finally started to show some signs of life, trending off of its lows on Monday.

That momentum helped facilitate yesterday’s run from a low of .04175 to .0712, which worked out to a healthy intraday pop of 80% on more than twice the monthly average volume. We want to continue to monitor this as a recovery play, as the regaining of even a portion of the ground that it lost in recent weeks would represent significant gains from the present juncture.

Cellectar Biosciences, Inc. CLRB

Speaking of bottom plays, there’s another one hitting our scanners this morning in CLRB. This stock found new 6-month lows yesterday, and from a technical standpoint, this is what can only be referred to as an incredibly ripe chart.

We’ve included a snapshot below, and as you can see, it currently boasts many of the characteristics that we constantly watch for, and often benefit from. Trading at recent relative lows, with an RSI indicating oversold, the MACD converging toward an impending bullish cross, and a sizable gap to the upside.

It’s for these reasons that CLRB must be afforded a spot on our watch-screens as we cruise through midweek.

Novus Acquisition & Development Corp. NDEV

After tagging NDEV in Monday’s morning report and witnessing a nice initial move from .30-.442 (+47%), we followed up yesterday and cautioned that a continuation of momentum made it necessary to stay on its trail, and we’re glad we did.

The stock produced a second straight solid session for us, running from its morning low of .43 to a new high of .559, a intraday pop of 30% and a two-day increase amounting to 86% High volume to the tune of more than five times its monthly average, and another strong close will keep NDEV’s slot on our radar safe for the time being.

Extended Watchlist:
ACAU, DTEA, ECTE, EXAD, PGUS, PLX(Bottom-Bouncer)